Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Nektar TherapeuticsNASDAQ: NKTR

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow grows, but more slowly than its trailing trend

Q2 FY2026 financing cash flow of $364.57M rose 172681.5% year over year, behind the +342086.6% change in trailing-twelve-month financing cash flow. Sequentially, it fell 31.2% from the prior quarter. Over 3 fiscal years it compounded at +392.9% a year.

Context

  • Financing cash flow amounted to 326.9% of revenue in FY2025, up 284.1 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +172681.5% toward the trailing-twelve-month pace of +342086.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$364.57M-31.2% QoQ
Last fiscal yearDec 2025
$180.57M+328.7% YoY
LTMJun 2026
$1.07B+342086.6% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+172681.5%——
1 year+328.7%——
3-year CAGR+392.9%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
180.57M USD
Year-over-year change
+328.7%
4-year CAGR
+49.4%

Financing Cash Flow vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +342086.6% is the highest of 9, against a peer median of +75.8%.
  • Financing cash flow amounts to 1968.3% of revenue for NKTR, versus a peer median of 209.2%.
NKTR Competitors
Financing Cash Flow for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NKTRNektar TherapeuticsLTM Jun 2026$1.07B USD+342086.6%+392.9%1968.3%
RCUSArcus Biosciences, Inc.LTM Jun 2026$313M USD+30.4%+145.5%267.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$226.9M USD+360.2%——
CHRSCoherus Oncology, Inc.LTM Mar 2026$219.85M USD+16.9%—468.9%
IMTXImmatics N.V.LTM Mar 2026€118.48M EUR-17.9%-8.9%317.7%
ANLAdlai Nortye Ltd.LTM Jun 2024$108.79M USD—-17.4%1676.2%
MGNXMacroGenics, Inc.LTM Mar 2026$69.59M USD+16083.5%+247.3%44.3%
IMCRImmunocore Holdings plcLTM Mar 2026$10.47M USD+121.3%-60.2%2.7%
XNCRXencor, Inc.LTM Jun 2026$8.3M USD-95.9%+13.0%7.9%
IPHAInnate Pharma S.A.FY2025€5.83M EUR+197.0%—209.2%
CGENCompugen Ltd.LTM Dec 2025$0 USD—+210.9%0.0%
Peer median (excluding NKTR) —+75.8%+13.0%209.2%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Depreciation & Amortization14.15M13.03M7.82M4.39M(4.49M)
Deferred Income Tax8.02M2.71M(140K)00
Stock-Based Compensation94.67M57.32M33.39M21.61M12.65M
Change in Working Capital(23.08M)492K(19.8M)(6.24M)(37.02M)
Accounts Receivables12.4M16.51M4.78M(3.05M)0
Inventory(509K)(3.4M)699K497K0
Accounts Payables(11.69M)3.1M(2.88M)2.67M(625K)
Other Working Capital(23.27M)(15.72M)(22.39M)(6.36M)(36.39M)
Other Non-Cash Items17.41M(9.36M)62.19M(76.51M)(15.58M)
Operating Cash Flow(412.66M)(304.01M)(192.61M)(175.71M)(208.51M)
Capital Expenditures(14.99M)(5.68M)(865K)(1.47M)(171K)
Acquisitions (Net)(217.77M)13.2M065.39M(697K)
Purchases of Investments(960.69M)(467.91M)(511.7M)(261.71M)(285.01M)
Sales of Investments1.18B826.23M650.88M340.36M284.68M
Other Investing Activities217.77M01.25M00
Investing Cash Flow202.78M365.84M139.56M142.57M(1.2M)
Debt Repayment00000
Common Stock Issued33.24M758K30K30.12M180.57M
Common Stock Repurchased000(3M)0
Dividends Paid00000
Other Financing Activities3M750K015M0
Financing Cash Flow36.24M1.51M30K42.12M180.57M
Effect of Forex Changes(92K)(327K)62K(4K)6K
Net Change in Cash(173.74M)63.01M(52.95M)8.98M(29.14M)
Free Cash Flow(427.65M)(309.68M)(193.47M)(177.18M)(208.68M)

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.